Titre : Membre-4 de la famille-12 des transporteurs de solutés

Membre-4 de la famille-12 des transporteurs de solutés : Questions médicales fréquentes

{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Membre-4 de la famille-12 des transporteurs de solutés : Questions médicales les plus fréquentes", "headline": "Membre-4 de la famille-12 des transporteurs de solutés : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Membre-4 de la famille-12 des transporteurs de solutés : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-06-17", "dateModified": "2025-03-14", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Membre-4 de la famille-12 des transporteurs de solutés" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Symporteurs des ions sodium-potassium-chlorure", "url": "https://questionsmedicales.fr/mesh/D028021", "about": { "@type": "MedicalCondition", "name": "Symporteurs des ions sodium-potassium-chlorure", "code": { "@type": "MedicalCode", "code": "D028021", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.543.585.937.875" } } }, "about": { "@type": "MedicalCondition", "name": "Membre-4 de la famille-12 des transporteurs de solutés", "alternateName": "Solute Carrier Family 12, Member 4", "code": { "@type": "MedicalCode", "code": "D064507", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Simon Franz Müller", "url": "https://questionsmedicales.fr/author/Simon%20Franz%20M%C3%BCller", "affiliation": { "@type": "Organization", "name": "Institute of Pharmacology and Toxicology, Faculty of Veterinary Medicine, Justus Liebig University Giessen, Schubertstr. 81, D-35392 Giessen, Germany." } }, { "@type": "Person", "name": "Joachim Geyer", "url": "https://questionsmedicales.fr/author/Joachim%20Geyer", "affiliation": { "@type": "Organization", "name": "Institute of Pharmacology and Toxicology, Faculty of Veterinary Medicine, Justus Liebig University Giessen, Schubertstr. 81, D-35392 Giessen, Germany." } }, { "@type": "Person", "name": "Nipaporn Deejai", "url": "https://questionsmedicales.fr/author/Nipaporn%20Deejai", "affiliation": { "@type": "Organization", "name": "Division of Molecular Medicine, Department of Research and Development, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand." } }, { "@type": "Person", "name": "Choochai Nettuwakul", "url": "https://questionsmedicales.fr/author/Choochai%20Nettuwakul", "affiliation": { "@type": "Organization", "name": "Division of Molecular Medicine, Department of Research and Development, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand." } }, { "@type": "Person", "name": "Nunghathai Sawasdee", "url": "https://questionsmedicales.fr/author/Nunghathai%20Sawasdee", "affiliation": { "@type": "Organization", "name": "Division of Molecular Medicine, Department of Research and Development, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Curcumin suppresses colorectal cancer by induction of ferroptosis via regulation of p53 and solute carrier family 7 member 11/glutathione/glutathione peroxidase 4 signaling axis.", "datePublished": "2024-06-04", "url": "https://questionsmedicales.fr/article/38837315", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/ptr.8258" } }, { "@type": "ScholarlyArticle", "name": "Solute carrier family 16 member 1 as a potential prognostic factor for pancreatic ductal adenocarcinoma and its influence on tumor immunity.", "datePublished": "2024-04-28", "url": "https://questionsmedicales.fr/article/38756638", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.21037/jgo-24-147" } }, { "@type": "ScholarlyArticle", "name": "Influence of Solute Carrier Family 22 Member 1 (SLC22A1) Gene Polymorphism on Metformin Pharmacokinetics and HbA1c Levels: A Systematic Review.", "datePublished": "2023-08-07", "url": "https://questionsmedicales.fr/article/37550919", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.2174/1573399820666230807145202" } }, { "@type": "ScholarlyArticle", "name": "A prospective diagnostic and prognostic biomarker for hepatocellular carcinoma that functions in glucose metabolism regulation: Solute carrier family 37 member 3.", "datePublished": "2023-02-09", "url": "https://questionsmedicales.fr/article/36773462", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.bbadis.2023.166661" } }, { "@type": "ScholarlyArticle", "name": "The solute carrier family 26 member 9 modifies rapidly progressing cystic fibrosis associated with homozygous F508del CFTR mutation.", "datePublished": "2024-06-07", "url": "https://questionsmedicales.fr/article/38852790", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.cca.2024.119765" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Acides aminés, peptides et protéines", "item": "https://questionsmedicales.fr/mesh/D000602" }, { "@type": "ListItem", "position": 3, "name": "Protéines", "item": "https://questionsmedicales.fr/mesh/D011506" }, { "@type": "ListItem", "position": 4, "name": "Protéines membranaires", "item": "https://questionsmedicales.fr/mesh/D008565" }, { "@type": "ListItem", "position": 5, "name": "Protéines de transport membranaire", "item": "https://questionsmedicales.fr/mesh/D026901" }, { "@type": "ListItem", "position": 6, "name": "Protéines transporteurs de solutés", "item": "https://questionsmedicales.fr/mesh/D000070590" }, { "@type": "ListItem", "position": 7, "name": "Symporteurs des ions sodium-potassium-chlorure", "item": "https://questionsmedicales.fr/mesh/D028021" }, { "@type": "ListItem", "position": 8, "name": "Membre-4 de la famille-12 des transporteurs de solutés", "item": "https://questionsmedicales.fr/mesh/D064507" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Membre-4 de la famille-12 des transporteurs de solutés - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Membre-4 de la famille-12 des transporteurs de solutés", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-03", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Membre-4 de la famille-12 des transporteurs de solutés", "description": "Comment diagnostiquer une dysfonction de SLC12A4 ?\nQuels tests sont utilisés pour évaluer SLC12A4 ?\nY a-t-il des marqueurs spécifiques pour SLC12A4 ?\nLes imageries médicales aident-elles au diagnostic ?\nLe diagnostic nécessite-t-il une biopsie ?", "url": "https://questionsmedicales.fr/mesh/D064507?page=2#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Membre-4 de la famille-12 des transporteurs de solutés", "description": "Quels sont les symptômes d'une anomalie de SLC12A4 ?\nLes symptômes varient-ils selon l'âge ?\nY a-t-il des symptômes spécifiques à surveiller ?\nLes symptômes sont-ils toujours présents ?\nLes symptômes peuvent-ils s'aggraver avec le temps ?", "url": "https://questionsmedicales.fr/mesh/D064507?page=2#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Membre-4 de la famille-12 des transporteurs de solutés", "description": "Comment prévenir les troubles liés à SLC12A4 ?\nY a-t-il des tests de dépistage recommandés ?\nLes conseils génétiques sont-ils utiles ?\nLes vaccinations influencent-elles SLC12A4 ?\nL'exercice physique aide-t-il à prévenir les symptômes ?", "url": "https://questionsmedicales.fr/mesh/D064507?page=2#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Membre-4 de la famille-12 des transporteurs de solutés", "description": "Quels traitements sont disponibles pour SLC12A4 ?\nLa thérapie génique est-elle une option ?\nLes changements alimentaires aident-ils ?\nDes traitements symptomatiques existent-ils ?\nLes traitements sont-ils personnalisés ?", "url": "https://questionsmedicales.fr/mesh/D064507?page=2#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Membre-4 de la famille-12 des transporteurs de solutés", "description": "Quelles complications peuvent survenir avec SLC12A4 ?\nLes complications sont-elles réversibles ?\nY a-t-il des risques de maladies associées ?\nLes complications affectent-elles la qualité de vie ?\nDes soins palliatifs sont-ils nécessaires ?", "url": "https://questionsmedicales.fr/mesh/D064507?page=2#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Membre-4 de la famille-12 des transporteurs de solutés", "description": "Quels sont les facteurs de risque pour SLC12A4 ?\nL'environnement influence-t-il SLC12A4 ?\nLe mode de vie joue-t-il un rôle ?\nLes infections augmentent-elles le risque ?\nL'âge est-il un facteur de risque ?", "url": "https://questionsmedicales.fr/mesh/D064507?page=2#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une dysfonction de SLC12A4 ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur des tests génétiques et des analyses biochimiques." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer SLC12A4 ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests de transport ionique et des analyses de sang peuvent être effectués." } }, { "@type": "Question", "name": "Y a-t-il des marqueurs spécifiques pour SLC12A4 ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Actuellement, il n'existe pas de marqueurs spécifiques largement reconnus." } }, { "@type": "Question", "name": "Les imageries médicales aident-elles au diagnostic ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Les imageries peuvent aider à évaluer des anomalies, mais ne sont pas spécifiques." } }, { "@type": "Question", "name": "Le diagnostic nécessite-t-il une biopsie ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Une biopsie n'est généralement pas nécessaire pour diagnostiquer SLC12A4." } }, { "@type": "Question", "name": "Quels sont les symptômes d'une anomalie de SLC12A4 ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes peuvent inclure des déséquilibres électrolytiques et des troubles neurologiques." } }, { "@type": "Question", "name": "Les symptômes varient-ils selon l'âge ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les symptômes peuvent se manifester différemment selon l'âge et le développement." } }, { "@type": "Question", "name": "Y a-t-il des symptômes spécifiques à surveiller ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Surveillez les signes de déshydratation et de fatigue excessive." } }, { "@type": "Question", "name": "Les symptômes sont-ils toujours présents ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Non, certains patients peuvent être asymptomatiques malgré une anomalie." } }, { "@type": "Question", "name": "Les symptômes peuvent-ils s'aggraver avec le temps ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, sans traitement, les symptômes peuvent s'aggraver avec le temps." } }, { "@type": "Question", "name": "Comment prévenir les troubles liés à SLC12A4 ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation équilibrée et une hydratation adéquate peuvent aider à prévenir les troubles." } }, { "@type": "Question", "name": "Y a-t-il des tests de dépistage recommandés ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Des tests génétiques peuvent être recommandés pour les familles à risque." } }, { "@type": "Question", "name": "Les conseils génétiques sont-ils utiles ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les conseils génétiques peuvent aider à évaluer le risque familial." } }, { "@type": "Question", "name": "Les vaccinations influencent-elles SLC12A4 ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Non, les vaccinations n'ont pas d'impact direct sur SLC12A4." } }, { "@type": "Question", "name": "L'exercice physique aide-t-il à prévenir les symptômes ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Un exercice régulier peut contribuer à une meilleure santé globale, mais pas spécifique." } }, { "@type": "Question", "name": "Quels traitements sont disponibles pour SLC12A4 ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Le traitement peut inclure des suppléments électrolytiques et des médicaments spécifiques." } }, { "@type": "Question", "name": "La thérapie génique est-elle une option ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "La thérapie génique est en recherche, mais pas encore une option standard." } }, { "@type": "Question", "name": "Les changements alimentaires aident-ils ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un régime équilibré peut aider à gérer les déséquilibres électrolytiques." } }, { "@type": "Question", "name": "Des traitements symptomatiques existent-ils ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des traitements symptomatiques peuvent être prescrits pour soulager les symptômes." } }, { "@type": "Question", "name": "Les traitements sont-ils personnalisés ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les traitements peuvent être adaptés en fonction des besoins individuels." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec SLC12A4 ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications peuvent inclure des troubles rénaux et des déséquilibres électrolytiques graves." } }, { "@type": "Question", "name": "Les complications sont-elles réversibles ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être réversibles avec un traitement approprié." } }, { "@type": "Question", "name": "Y a-t-il des risques de maladies associées ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des maladies métaboliques peuvent être associées à des anomalies de SLC12A4." } }, { "@type": "Question", "name": "Les complications affectent-elles la qualité de vie ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les complications peuvent significativement affecter la qualité de vie des patients." } }, { "@type": "Question", "name": "Des soins palliatifs sont-ils nécessaires ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Dans les cas graves, des soins palliatifs peuvent être envisagés pour le confort." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque pour SLC12A4 ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les antécédents familiaux et certaines conditions génétiques augmentent le risque." } }, { "@type": "Question", "name": "L'environnement influence-t-il SLC12A4 ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des facteurs environnementaux peuvent influencer l'expression de SLC12A4." } }, { "@type": "Question", "name": "Le mode de vie joue-t-il un rôle ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un mode de vie malsain peut exacerber les problèmes liés à SLC12A4." } }, { "@type": "Question", "name": "Les infections augmentent-elles le risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Certaines infections peuvent aggraver les symptômes liés à SLC12A4." } }, { "@type": "Question", "name": "L'âge est-il un facteur de risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'âge peut influencer la gravité des symptômes et des complications." } } ] } ] }

Sources (10000 au total)

Influence of Solute Carrier Family 22 Member 1 (SLC22A1) Gene Polymorphism on Metformin Pharmacokinetics and HbA1c Levels: A Systematic Review.

Solute Carrier Family 22 Member 1 (SLC22A1, also known as OCT1) protein has a vital role in the metabolism of metformin, a first-line anti-diabetes medication. Genetic polymorphism in SLC22A1 influenc... This review aims to compile the current knowledge about the effects of SLC22A1 genetic polymorphism on metformin pharmacokinetics and HbA1c levels.... We followed the PRISMA 2020 standards to conduct a systematic review. We searched the publications for all appropriate evidence on the effects of SLC22A1 genetic polymorphism on metformin pharmacokine... Initial database searches identified 7,171 relevant studies. We reviewed 155 titles and abstracts after deleting duplicates. After applying inclusion and exclusion criteria, 23 studies remained.... Three studies found that rs12208357, rs34059508, and G465R had a considerable impact (p < 0.05) on metformin pharmacokinetics, resulting in increased metformin plasma (Cmax), a higher active amount of...

A prospective diagnostic and prognostic biomarker for hepatocellular carcinoma that functions in glucose metabolism regulation: Solute carrier family 37 member 3.

Hepatocellular carcinoma (HCC) is the most common type of liver cancer. Due to the insidious onset of HCC, early diagnosis is relatively difficult. HCC also exhibit strong resistance to first-line the...

The solute carrier family 26 member 9 modifies rapidly progressing cystic fibrosis associated with homozygous F508del CFTR mutation.

Cystic fibrosis (CF) is an autosomal recessive disease caused by mutations to the CF transmembrane conductance regulator (CFTR). Symptoms and severity of the disease can be quite variable suggesting m... Exome sequencing was performed on six individuals carrying homozygous deltaF508 for CFTR genotype but present with rapidly progressing CF (RPCF). Data was analyzed using an unbiased genome-wide geneti... We have identified solute carrier family 26 member 9 (SLC26A9) as a modifier gene to be associated with RPCF Two rare missense SLC26A9 variants were discovered in three of six individuals deemed to ha... The enrichment of rare and potentially deleterious SLC26A9 mutations in patients with RPCF suggests SLC26A9 may act as an alternative anion transporter in CF and is a modifier gene associated with thi...

Comprehensive analysis of 33 human cancers reveals clinical implications and immunotherapeutic value of the solute carrier family 35 member A2.

Solute carrier family 35 member A2 (SLC35A2), which belongs to the SLC35 solute carrier family of human nucleoside sugar transporters, has shown regulatory roles in various tumors and neoplasms. Howev... We obtained the gene expression and protein levels of SLC35A2 in a variety of tumors from Molecular Taxonomy of Breast Cancer International Consortium, The Cancer Genome Atlas, Gene Expression Omnibus... SLC35A2 exhibited abnormally high or low expression in 23 cancers and was significantly associated with the prognosis. In various cancers, SLC35A2 expression and mammalian target of rapamycin complex ... Our study revealed that SLC35A2 is upregulated in 20 types of cancer, including lung adenocarcinoma (LUAD), breast invasive carcinoma (BRCA), colon adenocarcinoma (COAD), and lung squamous cell carcin...

Enhanced computed tomography radiomics predicts solute carrier family 7, member 11 in head and neck squamous cell carcinoma.

Traditional prognostic indicators for head and neck squamous cell carcinoma (HNSCC), such as clinicopathological features, human papillomavirus status, and imaging examinations, often lack precision i... We used patient genomic data and corresponding augmented CT images for prognostic analysis and building models. Further, we investigated the potential molecular mechanisms underlying SLC7A11 expressio... SLC7A11 expression level was high within tumor tissues and was connected to the infiltration of eosinophil, CD8... SLC7A11 is likely an important factor in the prognosis of HNSCC. SLC7A11 expression can be predicted effectively and reliably by radiomics models based on enhanced CT....

Hypersensitivity to ferroptosis in chromophobe RCC is mediated by a glutathione metabolic dependency and cystine import via solute carrier family 7 member 11.

Chromophobe (Ch) renal cell carcinoma (RCC) arises from the intercalated cell in the distal nephron. There are no proven treatments for metastatic ChRCC. A distinguishing characteristic of ChRCC is st...

An induced pluripotent stem cell line (MUSIi019-A) generated from a patient with distal renal tubular acidosis carrying a compound heterozygous mutation in solute carrier family 4 member 1 (SLC4A1) gene.

Distal renal tubular acidosis (dRTA), a disease characterized by the failure of the distal nephron to secrete acid into the urine, can be caused by mutations in SLC4A1 gene encoding erythroid and kidn...